학술논문

Dostarlimab (Dos) or pembrolizumab (Pem) plus chemotherapy (CT) in previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC): Patient (Pt) and disease characteristics subgroup analyses from the PERLA trial
Document Type
Journal
Source
JOURNAL OF THORACIC ONCOLOGY; APR 2023, 18 4, pS67-pS68, 2p. Supplement: S
Subject
Language
English
ISSN
15561380